Advertisement

La radiothérapie dans les cancers ovariens

  • L. Thomas
Part of the Abord clinique book series (ONCOLPRAT)

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Références

  1. 1.
    Delclos L, Dembo AJ (1973) Tumors of the ovary. In: Fletcher GH (ed) Texbook of radiotherapy Third Edition. Lea & Febiger, Philadelphie, p 834Google Scholar
  2. 2.
    Klaassen D, Shelley W, Starreveld A et al. (1988) Early stage ovarian cancer: a randomized clinical trial comparing whole abdominal radiotherapy, Melphalan, and intraperitoneal chromic phosphate: a National Cancer Institute of Canada Trials Group Report. J Clin Oncol 6: 1254–63PubMedGoogle Scholar
  3. 3.
    Vergote IB, Winderen M, DeVos LN et al. (1993) Intraperitoneal radioactive phosphorus therapy in ovarian carcinoma. Cancer 71: 2250–60PubMedGoogle Scholar
  4. 4.
    Goodman A, Bornstein L, Ball H et al. (1994) Chronic phosphate therapy in carcinoma of the ovary. J Am Coll Surg 179: 401–6PubMedGoogle Scholar
  5. 5.
    Tharp M, Hornback NB (1994) Complications associated with intraperitoneal 32P. Gynecol Oncol 53: 170–5CrossRefPubMedGoogle Scholar
  6. 6.
    Spanos WJ, Day T, Abner A et al. (1992) Complications in the use of intra-abdominal 32P for ovarian carcinoma. Gynecol Oncol 45: 243–7CrossRefPubMedGoogle Scholar
  7. 7.
    Rogers L, Varia M, Halle J et al. (1993) 32P following negative second look laparotomy for epithelial ovarian cancer. Gynecol Oncol 50: 141–6CrossRefPubMedGoogle Scholar
  8. 8.
    Peters WA, Smith MR, Cain JM et al. (1992) Intraperitoneal P-32 is not effective consolidation therapy after a negative second look laparotomy for epithelial carcinoma of the ovary. Gynecol Oncol 47: 146–9CrossRefPubMedGoogle Scholar
  9. 9.
    Spencer TR, Marks RD, Fenn JO et al. (1989) Intraperitoneal P-32 after negative second look laparotomy in ovarian carcinoma. Cancer 63: 2434–7PubMedGoogle Scholar
  10. 10.
    Young RC, Walton LA, Ellenberg SS et al. (1990) Adjuvant therapy in stage I and stage II. epithelial ovarian cancer. Results of two prospctive randomized trials. N Engl J Med. 322:1021–7PubMedGoogle Scholar
  11. 11.
    Young R, Nieberg R et al. (1999) Randomized clinical trial of adjuvant treatment of women with early (FIGO I-IIA high risk) ovarian cancer-GOG #95. Int J Gynecol Cancer 9: 11 (abstr. A33)Google Scholar
  12. 12.
    Vergote IB, Vergote de Vos LN, Abeler VM et al. (1992) Randomized trial comparing cisplatin with radioactive phosphorus or whole-abdomen irradiation as adjuvant treatment of ovarian cancer. Cancer 69: 741–9PubMedGoogle Scholar
  13. 13.
    Standards, options, recommandations. Tumeurs épithéliales malignes de l’ovaire (vol. 4) (1998) Fédération nationale des centres de lutte contre le cancer (ed). John Libbey Eurotext, MontrougeGoogle Scholar
  14. 14.
    Lhommé C, Ray-Coquard I, Guastalla JP et al. (2004) Recommandations pour la pratique clinique Standards, Options et Recommandations 2003 pour le traitement médical de première ligne des patientes atteintes de tumeurs épithéliales malignes de l’ovaire, mise à jour (rapport abrégé). Bull Cancer 91: 609–20PubMedGoogle Scholar
  15. 15.
    Dembo AJ (1983) Radiation therapy in the management of ovarian cancer. Clin Obstet Gynaecol 10: 261–78PubMedGoogle Scholar
  16. 16.
    Fletcher GH, Shukovsky LJ (1975) The interplay of radiocurability and tolerance in the irradiation of human cancers. J Radiol Electrol Med Nucl 56: 383–400PubMedGoogle Scholar
  17. 17.
    Dembo AJ (1992) Epithelial ovarian cancer: the role of radiotherapy. Int J Radiat Oncol Biol Phys 22: 835–45PubMedGoogle Scholar
  18. 18.
    Haie C, Pejovic-Lenfant MH, George M et al. (1989) Whole abdominal irradiation following chemotherapy in patients with minimal residual disease after second look surgery in ovarian carcinoma. Int J Radiat Oncol Biol Phys 17: 15–9PubMedGoogle Scholar
  19. 19.
    Delouche G, Valinta D, Bachelot F et al. (1981) Radiothérapie des cancers épithéliaux de l’ovaire. Irradiation totale de l’abdomen par champs orthogonaux. J Eur Radiother 2: 103–17Google Scholar
  20. 20.
    Thomas L, Pigneux J, Chauvergne J et al. (1993) Irradiation abdomino-pelvienne des cancers ovariens par 4 faisceaux orthogonaux: technique tolérance, complications. Bull Cancer Radiother 80: 241–8Google Scholar
  21. 21.
    Duthoy W, De Gersem W, Vergote K, et al. (2003) Whole abdominopelvic radiotherapy (WAPRT) using intensity-modulated arc therapy (IMAT): first clinical experience. Int J Radiat Oncol Biol Phys 57: 1019–32CrossRefPubMedGoogle Scholar
  22. 22.
    Thomas L, Pigneux J, Chauvergne J et al. (1994) Evaluation of whole abdominal irradiation in ovarian carcinoma with a four orthogonal fields technique. Int J Radiat Oncol Biol Phys 30: 1083–90PubMedGoogle Scholar
  23. 23.
    Fyles AW, Dembo AJ, Bush RS et al. (1992) Analysis of complications in patients treated with abdomino-pelvic radiation therapy for ovarian carcinoma. Int J Radiat Oncol Biol Phys 22: 847–51PubMedGoogle Scholar
  24. 24.
    Whelan TJ, Dembo AJ, Bush RS et al. (1992) Complications of whole abdominal and pelvic radiotherapy following chemotherapy for advanced ovarian cancer. Int J Radiat Oncol Biol Phys 22: 853–8PubMedGoogle Scholar
  25. 25.
    Van Bunningen B, Bouma J, Kooijman C et al. (1988) Total abdominal irradiation in stage I and II carcinoma of the ovary. Radiother Oncol 11: 305–10PubMedGoogle Scholar
  26. 26.
    Firat S, Murray K, Erickson B (2003) High-dose whole abdominal and pelvic irradiation for treatment of ovarian carcinoma: long-term toxicity and outcomes. Int J Radiat Oncol Biol Phys 57: 201–7CrossRefPubMedGoogle Scholar
  27. 27.
    Sell A, Bertelsen K, Andersen JE et al. (1990) Randomized study of whole-abdomen irradiation versus pelvic irradiation plus cyclophosphamide in treatment of early ovarian cancer. Gynecol Oncol 37: 367–73CrossRefPubMedGoogle Scholar
  28. 28.
    Chiara S, Conte P, Franzone P et al. (1994) High-risk early-stage ovarian cancer. Randomized clinical trial comparing cisplatin plus cyclophosphamide versus whole abdominal radiotherapy. Am J Clin Oncol 17: 72–6PubMedGoogle Scholar
  29. 29.
    Kojs Z, Glinski B, Reinfuss M et al. (2001) Résultat d’un essai randomisé comparant une radiothérapie abdomino-pelvienne postopératoire et une chimiothérapie postopératoire dans les cancers de l’ovaire précoces. Cancer Radiother 5: 5–11PubMedGoogle Scholar
  30. 30.
    Colombo N, Guthrie D, Chiari S et al. (2003) International Collaborative Ovarian Neoplasm trial 1: a randomized trial of adjuvant chemotherapy in women with early-stage ovarian cancer. J Natl Cancer Inst 95: 125–32PubMedGoogle Scholar
  31. 31.
    Trimbos JB, Vergote I, Bolis G et al. (2003) Impact of adjuvant chemotherapy and surgical staging in early-stage ovarian carcinoma: European Organisation for Research and Treatment of Cancer-Adjuvant ChemoTherapy in Ovarian Neoplasm trial. J Natl Cancer Inst 95: 113–25PubMedGoogle Scholar
  32. 32.
    Einhorn N, Trope C, Ridderheim M et al. (2003) A systematic overview of radiation therapy effects in ovarian cancer. Acta Oncol 42: 562–6PubMedGoogle Scholar
  33. 33.
    Menczer J, Ben-Baruch G, Modan M et al. (1989) Intraperitoneal cisplatin chemotherapy versus abdominopelvic irradiation in varian carcinoma patients after second look laparotomy. Cancer 63: 1509–13PubMedGoogle Scholar
  34. 34.
    Podczaski E, Manetta A, Kaminski P et al. (1990) Survival of patients with ovarian epithelial carcinomas after second look laparotomy. Gynecol Oncol 36: 43–7CrossRefPubMedGoogle Scholar
  35. 35.
    Creasman WT, Gall S, Bundy BN et al. (1989) Second-look laparotomy in the patient with minimal residual stage III ovarian cancer (a Gynecologic Oncology Group Study). Gynecol Oncol 35: 378–82PubMedGoogle Scholar
  36. 36.
    Rubin SC, Hoskins WJ, Saigo PE et al. (1991) Prognostic factors for recurrence following negative second look laparotomy in ovarian cancer patients treated with platinum-based chemotherapy. Gynecol Oncol 42: 137–41PubMedGoogle Scholar
  37. 37.
    Franchin G, Tumolo S, Scarabelli C et al. (1991) Whole abdomen radiation therapy after a short chemotherapy course and second look laparotomy in advanced ovarian cancer. Gynecol Oncol 1991; 41: 206–11Google Scholar
  38. 38.
    Thomas GM (1993) Is there a role for consolidation or salvage radiotherapy after chemotherapy in advanced epithelial ovarian cancer? Gynecol Oncol 51: 97–103CrossRefPubMedGoogle Scholar
  39. 39.
    Bruzzone M, Repetto L, Chiara S et al. (1990) Chemotherapy versus radiotherapy in the management of ovarian cancer patients with pathological complete response or minimal residual disease at second look. Gynecol Oncol 38: 392–5CrossRefPubMedGoogle Scholar
  40. 40.
    Lambert HE, Rustin GJS, Gregory WM et al. (1993) A randomized trial comparing singleagent carboplatin with carboplatin followed by radiotherapy for advanced ovarian cancer: a North Thames Ovary Group Study. J Clin Oncol 11: 440–8PubMedGoogle Scholar
  41. 41.
    Mangioni C, Epis A, Vassena L et al. (1987) Radiotherapy versus chemotherapy as second line treatment of minimal residual disease in advanced epithelial ovarian cancer. Proc International Gynecologic Cancer Society, 49Google Scholar
  42. 42.
    Sorbe B on behalf of the Swedish-Norgewian Ovarian Cancer Study Group (2003) Consolidation treatment of advanced (FIGO stage III) ovarian carcinoma in complete surgical remission after induction chemotherapy: a randomized, controlled, clinical trial comparing whole abdominal radiotherapy, chemotherapy, and no further treatment. Int J Gynecol Cancer 13: 278–86Google Scholar
  43. 43.
    Debby A, Levy T, Hayat H et al. (2004) Whole-abdomen, single-dose consolidation radiotherapy in patients with pathologically confirmed complete remission of advanced ovarian epithelial carcinoma: a long-term survival analysis. Int J Gynecol Cancer 14: 794–8CrossRefPubMedGoogle Scholar

Copyright information

© Springer-Verlag France 2006

Authors and Affiliations

  • L. Thomas

There are no affiliations available

Personalised recommendations